Consolidated Statement of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Treasury Stock	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Common stock, beginning balance (in shares) at Jan. 31, 2023		69,906,586
Beginning balance at Jan. 31, 2023	$ 739,508	$ 70	$ 2,276,694	$ (1,319)	$ (905)	$ (1,535,032)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock option exercises (in shares)		953,643
Stock option exercises	6,808	$ 1	6,807
Vesting of restricted stock units (in shares)		1,690,527
Vesting of restricted stock units	2	$ 2
Vesting of performance stock units (in shares)		22,991
Issuance of common stock in connection with a business combination	0
Stock-based compensation	456,907		456,907
Issuance of common stock under the Employee Stock Purchase Plan (in shares)		167,574
Issuance of common stock under the Employee Stock Purchase Plan	36,914		36,914
Unrealized gain (loss) on available-for-sale securities	4,652				4,652
Foreign currency translation adjustment	798				798
Net loss	(176,600)					(176,600)
Common stock, ending balance (in shares) at Jan. 31, 2024		72,741,321
Ending balance at Jan. 31, 2024	1,068,989	$ 73	2,777,322	(1,319)	4,545	(1,711,632)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock option exercises (in shares)		267,931
Stock option exercises	2,026		2,026
Vesting of restricted stock units (in shares)		1,529,981
Vesting of restricted stock units	1	$ 1
Vesting of performance stock units (in shares)		77,444
Issuance of common stock in connection with a business combination	0
Stock-based compensation	493,940		493,940
Conversion of redeemable convertible preferred stock to common stock (in shares)		5,662,979
Conversion of convertible senior notes	1,145,324	$ 4	1,145,320
Issuance of common stock under the Employee Stock Purchase Plan (in shares)		188,155
Issuance of common stock under the Employee Stock Purchase Plan	36,047		36,047
Unrealized gain (loss) on available-for-sale securities	(690)				(690)
Foreign currency translation adjustment	(4,779)				(4,779)
Reclassification of derivative related to the Capped Call associated with the 2024 Notes	169,692		169,692
Other	746		746
Net loss	(129,072)					(129,072)
Common stock, ending balance (in shares) at Jan. 31, 2025		80,467,811
Ending balance at Jan. 31, 2025	$ 2,782,224	$ 78	4,625,093	(1,319)	(924)	(1,840,704)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock option exercises (in shares)	403,516	403,516
Stock option exercises	$ 3,183		3,183
Vesting of restricted stock units (in shares)		1,673,239
Vesting of restricted stock units	2	$ 2
Vesting of performance stock units (in shares)		91,319
Shares withheld related to net share settlement of equity awards (in shares)		(296,897)
Shares withheld related to net share settlement of equity awards	(108,378)		(108,378)
Issuance of common stock in connection with a business combination subject to future vesting (in shares)		213,023
Issuance of common stock in connection with a business combination (in shares)		484,169
Issuance of common stock in connection with a business combination	141,402	$ 1	141,401
Stock-based compensation	$ 550,454		550,454
Repurchases of common stock (in shares)	(1,576,109)	(1,576,109)
Repurchases of common stock	$ (400,333)			(400,333)
Issuance of common stock under the Employee Stock Purchase Plan (in shares)		235,218
Issuance of common stock under the Employee Stock Purchase Plan	40,824		40,824
Settlement of the Capped Call associated with the 2026 Notes (in shares)		(1,182,670)
Settlement of the Capped Call associated with the 2026 Notes	0		92,917	(92,917)
RSA forfeitures (in shares)		(19,845)
Unrealized gain (loss) on available-for-sale securities	4,126				4,126
Foreign currency translation adjustment	10,005				10,005
Net loss	(71,151)					(71,151)
Common stock, ending balance (in shares) at Jan. 31, 2026		80,492,774
Ending balance at Jan. 31, 2026	$ 2,952,358	$ 81	$ 5,345,494	$ (494,569)	$ 13,207	$ (1,911,855)